Post-Conference Perspectives: RxPONDER, SABCS 2020

Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD, discuss the practice-changing results and real-world implications of the RxPONDER trial for patients with HR+ HER2- breast cancer.

EP. 1: HR+ Breast Cancer: Oncotype DX RS and TAILORx

May 10th 2021

Experts in breast cancer provide a historic perspective on the use of the Oncotype DX recurrence score (RS) in patients with HR+, HER- breast cancer and review practical implications from the TAILORx trial.

EP. 2: RxPONDER Trial in HR+ Operable Breast Cancer

May 10th 2021

Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD, review recent results from the RxPONDER trial looking at the predictive value of the Oncotype DX RS on benefit of adjuvant chemotherapy in women with lymph node-positive, HR+, HER2- breast cancer.

EP. 3: HR+ Breast Cancer: Practical Implications of RxPONDER

May 10th 2021

The practice-changing results and implications from the RxPONDER trial for early-stage HR+ breast cancer is discussed.

EP. 4: NCCN Guideline Updates for HR+ Operable Breast Cancer

May 17th 2021

Experts in breast cancer comment on NCCN guideline recommendations as they reflect the outcomes of the RxPONDER trial for HR+ early breast cancer.

EP. 5: HR+ Breast Cancer: Impact of RxPONDER on Clinical Practice

May 17th 2021

Questions to consider when approaching the treatment of HR+, HER2-breast cancer based on the RxPONDER trial results.

EP. 6: HR+ Breast Cancer: Role of RxPONDER Data in Clinical Practice

May 17th 2021

Lajos Pusztai, MD, PhD, and Priyanka Sharma, MD, share closing thoughts on additional data they hope to see from the RxPONDER trial, and using these data in clinical practice for the treatment of HR+ early breast cancer.